Keywords
COVID-19
Vaccine
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Understand the characteristics and outcomes of COVID-19 vaccine-related myocarditis. Bibliographic review: Rare events, such as pericarditis and myocarditis, have been reported in patients receiving mRNA vaccines from companies such as Pfizer and Moderna. These events usually occur within the first 14 days of vaccination and are more common after the second dose and in men between the ages of 12 and 30. The main symptoms are chest pain, shortness of breath, or palpitations. It is necessary to confirm the diagnosis with complementary tests, which are performed in a hospital emergency room. This evaluation includes electrocardiogram, dosage of cardiac necrosis markers (troponin and CK-MB), and imaging tests (echocardiogram, CT scan, or MRI) included in the evaluation. Treatment is supportive and symptomatic for pain control. The known risks of COVID-19 and its potentially serious complications, such as post-COVID-19 conditions, hospitalization, and death, far outweigh the potential risks of a rare adverse reaction to vaccination, including the potential risk of myocarditis or pericarditis. Final considerations: The risk-benefit analysis of the COVID-19 mRNA vaccines yields positive results in favor of vaccination, as the number of cases prevented is exponentially greater than the number of adverse events reported.
References
CALOFORIO ALP, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J., 2013; 34(33):2636-48.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Myocarditis and Pericarditis After mRNA COVID-19 Vaccination, 2022. Disponível em: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html. Acessado em: 02 de outubro de 2022.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Selected adverse events reported after COVID-19 vaccination. Centers for Disease Control and Prevention, 2021. Disponível em: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html. Acessado em: 02 de outubro de 2022.
COSTANZO-NORDIN MR, et al. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol, 1985;6(5):1078-82.
FERNÁNDEZ-SOLÀ J. The Effects of Ethanol on the Heart: Alcoholic Cardiomyopathy. Nutrients, 2020;12(2):572.
GARGANO, J. et al. Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 2021; 70(27977).
HOWLETT JG, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol, 2009;25(2):85-105.
LE VU S, et al. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun, 2022; 13, 3633.
MAHRHOLDT H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation, 2004;109(10):1250-8.
MARON BJ, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 2006;113(14):1807-16.
MARSHALL, M. et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics, Elk Grove Village Il, 2021; 148(3).
MEVORACH D, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 2021; 2;385(23):2140-2149.
MEVORACH D, et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N Engl J Med, 2022; 386(10):998-999.
MONTERA MW, et al. I Diretriz brasileira de miocardites e pericardites.Arq. Bras. Cardiol, 2013; 4(1).
NORDIN S, et al. Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy. Journal of the American College of Cardiology, 2016; 68(15):1707-1708.
OSTER ME, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA, 2022;327(4):331-340.
PATRIKI D, et al. A Prospective Pilot Study to Identify a Myocarditis Cohort who may Safely Resume Sports Activities 3 Months after Diagnosis. J Cardiovasc Transl Res. 2021;14(4):670-673.
POLLACK A, et al. Viral myocarditis--diagnosis, treatment options, and current controversies. Nat Rev Cardiol, 2015;12(11):670-80.
POLLARD CA, et al. The COVID-19 pandemic: a global health crisis. Physiol Genomics, 2020; 52(11): 549–557.
SAGAR S, et al. Myocarditis. Lancet, 2012; 379(9817): 738–747.
SALAH HM e MEHTA JL. COVID-19 Vaccine and Myocarditis. Am J Cardiol., 2021; 157: 146–148.
TSCHÖPE C, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol, 2021;18(3):169-193.
WITBERG G, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med, 2021; 385:2132–2139.